New eye disease drug enters human testing phase
NCT ID NCT06569758
Summary
This early-stage study aims to test the safety and side effects of a new injectable drug called GenSci098 in people with thyroid eye disease. Researchers will give increasing doses to 76 participants to see how their bodies handle the medication and monitor for any problems. The main goal is to determine if the drug is safe enough for further testing, not to treat the disease at this stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication
RECRUITINGShanghai, Shanghai Municipality, 200011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.